Peptide News Digest

Nature TransCODE Peptideins Map +10% of Human Proteome, Novo Q1 Wegovy 65% New-Rx + CagriSema Single-Chamber Cut, Lisata-Kuva Amendment, Lilly Quintuple Agonist ADA Slot

Nature TransCODE peptideins paper, Novo Q1 sub-detail (Wegovy 65% new-Rx, CagriSema co-formulation cut), Jefferies pushback, Lisata-Kuva amendment, Lilly quintuple agonist.

10 stories · Covering research, industry, regulatory, clinical-trials

Editor's Note

May 7 surfaced a substantial Nature paper from the international TransCODE Consortium expanding the human proteome by roughly 10% via 1,785 newly recognized microproteins from non-canonical open reading frames — the consortium codified the term 'peptideins' for the most ambiguous functional category. The post-Novo-Q1 news cycle continued to deliver: CEO Mike Doustdar's CNBC interview confirmed Wegovy holds 65% of all new US GLP-1 prescriptions and called the moment a 'turnaround situation,' and Q1 documents also revealed Novo terminated the single-chamber CagriSema co-formulation device (the dual-chamber system continues), with Jefferies pushing back that the lower-end of the tightened guidance hadn't moved enough to be a positive surprise. On the M&A side, Lisata Therapeutics' Kuva Labs merger gained a May 3 amendment and waiver, with the $5/share + $1 CVR tender offer for the certepetide cyclic peptide oncology asset on track to close in Q2. Lantheus's PNT2003 — a Lutathera radioequivalent for SSTR2 neuroendocrine tumors — moves into its final FDA approval window after the 30-month regulatory stay expires June 2026. Crinetics reports Q1 after-market today with Palsonify EU launch detail and CRN09682 SSTR2 NDC BRAVESST2 progress expected. Eli Lilly + Indiana Biosciences disclosed a quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal-data slot at ADA 2026 May 29, distinct from the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ quintuple Nature paper. A Frontiers in Aging review consolidated the case for therapeutic peptides in gerontology, Bicycle Therapeutics reported Q1 with $559.5M cash and a runway to 2030, and CNBC documented LifeMD's new-patient volume doubling to tripling on Wegovy pill demand.

Research

Nature (May 6): TransCODE Consortium Adds 1,785 Microproteins to Human Proteome — Expanding It by ~10% and Codifying 'Peptideins' Conceptual Framework

The international TransCODE Consortium published a Nature paper May 6 reporting that roughly 25% of 7,264 non-canonical open reading frames (ncORFs) give rise to detectable peptides, based on a meta-analysis of 95,520 proteomics experiments. The work identifies 1,785 previously unrecognized microproteins, expands the human proteome by ~10%, and introduces the conceptual model of 'peptideins' — microproteins with indeterminate functional potential. Most peptideins are under 50 amino acids and lack similarity to traditional proteins. The consortium, launched in 2022, includes GENCODE, PeptideAtlas, HUPO-HPP, and HUPO-HIPP and aims to set the reference annotation standard for ncORF-encoded microproteins.

#nature #transcode-consortium #microproteins #peptideins #proteomics #ncorf
Industry

Novo Nordisk Q1 May 6 Detail: Wegovy at 65% of US New GLP-1 Prescriptions — CEO Calls It 'Turnaround Situation'; Single-Chamber CagriSema Co-Formulation Discontinued

Novo Nordisk CEO Mike Doustdar told CNBC May 6 that the Wegovy brand now holds 65% of all new US GLP-1 prescriptions and characterized the moment as a 'turnaround situation' for the franchise. The Q1 print also disclosed that Novo has terminated the single-chamber CagriSema co-formulation project 'due to portfolio considerations' — the dual-chamber injectable system continues, with the original FDA filing already submitted and a decision expected late 2026. The CEO insisted plans for the CagriSema launch remain on track despite the device change. CNBC also documented LifeMD's new-patient volume jumping from 300–400/day before the Wegovy pill launch to 600–1,000/day after.

#novo-nordisk #wegovy #cagrisema #doustdar #lifemd #single-chamber
Industry

Jefferies on Novo Q1: 'Lower End of Guidance Not Lifted More Will Be Seen as Negative' — Sell-Side Counterweight to the Wegovy-Pill Beat

Jefferies analysts pushed back May 6 against the otherwise-positive market reaction to Novo Nordisk's Q1, arguing that the change in full-year guidance (tightened from a 5–13% sales-and-operating-profit decline to a 4–12% decline) was unlikely to lift consensus forecasts and could even contract them: 'we suspect the fact that the company has not lifted the lower end of the guidance range more will be seen as a negative.' The framing matters because NVO US-listed shares had already risen ~6% on the print, and the price-war pressure on the GLP-1 class — with Wegovy pill running at $149/month for the 1.5 mg starter dose against intensifying Foundayo competition — leaves the lower-end risk path open through year-end.

#jefferies #novo-nordisk #q1-2026 #guidance #analyst-pushback #glp-1-class
Industry

Lisata Therapeutics + Kuva Labs Merger Amendment (May 3 SEC 8-K): $5/Share + $1 CVR Tender Offer for Certepetide Cyclic Peptide Oncology Asset, Q2 Closing on Track

Lisata Therapeutics filed a May 3 SEC 8-K disclosing an Amendment and Waiver to the Merger Agreement with Kuva Labs Inc. The original definitive agreement (March 6, 2026) priced the all-cash tender at $5.00/share plus a $1.00 contingent value right per share — payable if a regulatory filing for certepetide is submitted or accepted in any jurisdiction within seven years. Closing is expected in Q2 2026. Certepetide is Lisata's cyclic peptide CendR-platform tumor-microenvironment modulator; the lead Phase 2 ASCEND trial in metastatic pancreatic ductal adenocarcinoma reported encouraging Cohort A data, and a Phase 1b/2a trial in locally advanced non-resectable PDAC is also active. Kuva is a cancer imaging company expanding into therapeutics through the deal.

#lisata-therapeutics #kuva-labs #certepetide #cyclic-peptide #pancreatic-cancer #merger
Regulatory

Lantheus PNT2003 — Lutathera Lu-177 Dotatate Radioequivalent — Moves Into Final FDA Approval Window After 30-Month Regulatory Stay Expires June 2026

Lantheus's PNT2003 (lutetium Lu 177 dotatate ANDA-route radioequivalent) is positioned to enter its final FDA approval window after the 30-month regulatory stay expires in June 2026. The product would be the second SSTR2 PRRT in the US neuroendocrine tumor market alongside Novartis's Lutathera, which has held the category since 2018. The regulatory framework: PNT2003 received tentative approval March 2; PYLARIFY TruVu (piflufolastat F 18) high-throughput PSMA PET formulation approved March 6. ITM's Lu-edotreotide-177 (ITM-11) follows on a separate August 28, 2026 PDUFA, and Crinetics' CRN09682 SSTR2 non-peptide drug conjugate is in Phase 1/2 BRAVESST2 — making 2026 a defining year for the SSTR2 PRRT competitive frame.

#lantheus #pnt2003 #lutathera #radioequivalent #neuroendocrine-tumors #sstr2 #prrt
Industry

Crinetics Q1 2026 Set for May 7 After-Market Close: Palsonify EU Launch Detail + CRN09682 SSTR2 NDC BRAVESST2 Update Expected

Crinetics Pharmaceuticals reports Q1 2026 financial results after market close May 7, with a 4:30 p.m. ET conference call. Investors will be looking for first commercial color on Palsonify (paltusotine), the once-daily oral SST2 nonpeptide agonist that won European Commission approval April 27 for adult acromegaly across the 27 EU member states plus three EEA countries (Iceland, Liechtenstein, Norway). First launches are planned for Germany and Austria. Q1 commentary on CRN09682 — the first-in-class SSTR2 non-peptide drug conjugate currently in Phase 1/2 BRAVESST2 in metastatic neuroendocrine tumors — is also expected, with the program designed as a direct challenge to peptide-based PRRT including Lutathera and Perspective Therapeutics' alpha-PRRT.

#crinetics #q1-2026 #palsonify #paltusotine #crn09682 #sstr2
Clinical Trials

Eli Lilly + Indiana Biosciences Quintuple Agonist (GLP-1/GIP/Glucagon/Amylin/Calcitonin) Animal Data Set for ADA 2026 May 29 Plenary

Eli Lilly, with the Indiana Biosciences Research Institute, has disclosed an ADA Scientific Sessions Late-Breaking Poster slot (Poster 2839-LB, May 29) for a single peptide molecule that simultaneously activates five receptors: GLP-1, GIP, glucagon, amylin, and calcitonin. Lead investigator Jonathan Douros, PhD, will present rodent data showing weight-loss superiority over retatrutide in Lilly-sponsored animal studies. The compound is distinct from the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ quintuple agonist published in Nature on April 30 — that one is a peptide-drug conjugate combining GLP-1/GIP with the pan-PPAR agonist lanifibranor, while the Lilly + Indiana Biosciences molecule appears to be a single peptide hitting all five receptors directly. Both signal that the obesity-pharmacology ceiling is moving past the triple-agonist generation.

#eli-lilly #indiana-biosciences #quintuple-agonist #ada-2026 #amylin #calcitonin #preclinical
Research

Frontiers in Aging 2026 Review: Therapeutic Peptides in Gerontology — Mechanisms and Applications for Healthy Aging

A 2026 Frontiers in Aging review consolidates the case for therapeutic peptides as gerontology agents, mapping mechanisms across mitochondrial-derived peptides (MOTS-c, humanin), thymic peptides (thymosin alpha-1), wound-and-tissue-repair peptides (BPC-157, TB-500), copper peptides (GHK-Cu), and growth-hormone secretagogues (CJC-1295, ipamorelin). The review frames the longevity peptide field as a clinical category that now sits alongside GLP-1 metabolic medicine — driven by Hims & Hers' 2026 longevity-specialty launch, Drexel's May 5 Q&A on peptide popularity, and the FDA Category 2 removal of 12 peptides on April 22. The piece also flags that BPC-157, TB-500, and most wellness peptides still lack published human RCTs, with clinical use largely based on case reports and preclinical mechanistic rationale.

#frontiers-in-aging #gerontology #longevity #mots-c #thymosin #bpc-157 #ghk-cu
Industry

Bicycle Therapeutics Q1 2026 (April 30): $559.5M Cash, Cash Runway to 2030, $60.8M Net Loss; Nuzefatide Pevedotin Duravelo-2 Dose-Selection Heading to ASCO 2026

Bicycle Therapeutics reported Q1 2026 financial results April 30 — net loss of $60.8M ($0.87 per share) on R&D of approximately $44M, with $559.5M in cash and equivalents at March 31 supporting a cash runway into 2030. The pipeline update reaffirmed that nuzefatide pevedotin (BT5528) Duravelo-2 dose-selection data in EphA2-positive solid tumors will be presented at the ASCO 2026 Rapid Oral Abstract Session on June 1, the Phase 2 nuzefatide pevedotin trial in recurrent pancreatic cancer enrolled its first patient in April, and the EphA2 gallium-68 PET imaging program continues to accumulate first-in-human data. Bicycle remains the leading bicyclic-peptide-platform pure-play in oncology.

#bicycle-therapeutics #q1-2026 #nuzefatide-pevedotin #duravelo-2 #asco-2026 #epha2
Industry

CNBC: Wegovy Pill Drives LifeMD New-Patient Surge from 300–400/Day Pre-Launch to 600–1,000/Day Post-Launch

CNBC's May 6 Wegovy-Q1 piece documented LifeMD new-patient volume jumping from 300–400 per day before the Wegovy pill January 5 launch to 600–1,000 per day after, with the telehealth platform crediting the pill format and improved insurance coverage for unlocking a wave of GLP-1-curious patients who had not previously committed to injectables. LifeMD has been one of the most exposed independent pure-play telehealth obesity platforms during the Novo channel-expansion era, and its data point feeds the broader 'oral GLP-1 expands the market' thesis that Lilly's Foundayo team also referenced on the April 30 Q1 call (where 80% of Foundayo patients were new to the GLP-1 class).

#lifemd #wegovy-pill #telehealth #novo-nordisk #patient-volume #oral-glp-1